









Markets
/
Stocks
/
nasdaq-aray
/

Accuray Inc

ARAY

1.670USD

-0.070-4.02%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

188.12MMarket Cap

LossP/E TTM



Accuray Inc

1.670

-0.070-4.02%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

63 / 207

Overall Ranking

144 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

5.500

Target Price

+216.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.

Undervalued

The company’s latest PE is -107.88, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 68.05M shares, decreasing 6.33% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 5.37M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.95, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 127.54M, representing a year-over-year decrease of 5.02%, while its net profit experienced a year-over-year decrease of 66.84%.

Score

Industry at a Glance

Previous score

6.95

Change



Financials

5.44

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.13

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.49

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -112.40, which is -88.89% below the recent high of -12.49 and 69.43% above the recent low of -34.37.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 63/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Accuray Inc is 5.00, with a high of 7.00 and a low of 4.50.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

5.500

Target Price

+216.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Accuray Inc

ARAY

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.22, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.83 and the support level at 1.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.22

Change

-0.47

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.019

Buy

RSI(14)

60.577

Neutral

STOCH(KDJ)(9,3,3)

71.937

Neutral

ATR(14)

0.077

High Vlolatility

CCI(14)

153.946

Buy

Williams %R

28.814

Buy

TRIX(12,20)

0.461

Sell

StochRSI(14)

28.384

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.644

Buy

MA10

1.608

Buy

MA20

1.570

Buy

MA50

1.460

Buy

MA100

1.449

Buy

MA200

1.705

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 66.06%, representing a quarter-over-quarter decrease of 0.39%. The largest institutional shareholder is The Vanguard, holding a total of 5.37M shares, representing 4.77% of shares outstanding, with 9.34% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.21M

+1.76%

Aevum Fondation de Prévoyance

5.40M

+5.06%

The Vanguard Group, Inc.

Star Investors

5.29M

+0.10%

Neuberger Berman, LLC

5.52M

+0.08%

Heartland Advisors, Inc.

4.27M

+11.77%

Armistice Capital LLC

2.54M

+105.18%

Renaissance Technologies LLC

Star Investors

2.72M

-8.61%

Geode Capital Management, L.L.C.

2.25M

+2.78%

State Street Global Advisors (US)

1.94M

+0.00%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.21, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.